QuantalX Neuroscience has announced the U.S. launch of Delphi‑MD, a non-invasive system designed to provide direct and quantitative assessment of functional brain networks. This follows the recent De Novo classification by the Food and Drug Administration (FDA), which created a new regulatory category for functional brain network assessment.
Delphi‑MD is now being implemented at several major academic and clinical institutions across the United States. The system aims to give healthcare professionals, including neurologists, psychiatrists, neurosurgeons, and rehabilitation teams, access to real-time, objective data on brain network function. It uses a combination of transcranial magnetic stimulation (TMS), electroencephalography (EEG), proprietary analytics algorithms, and an integrated normative database that accounts for age differences.
Dr. Iftach Dolev, Founder & CEO of QuantalX Neuroscience, stated: “For decades, clinicians have relied primarily on structure and symptoms to guide neurological care. With Delphi‑MD, we are bringing objective, functional brain data into everyday clinical practice, giving care teams a direct, quantitative signal of how brain networks are actually performing. Our commercialization in the U.S. marks a critical step toward making functional brain assessment as routine and actionable as an EKG stress test.”
The company’s Chief Commercial Officer Klaus Dahmen is leading efforts to bring Delphi-MD into research and healthcare centers such as Mount Sinai Health System’s Enhanced Stroke Recovery Program; University of Pennsylvania’s BrainSTIM Center; Mass General Brigham / Massachusetts General Hospital’s Brain Recovery Lab; University of Pennsylvania TBI Clinical Research Center; UCSF Pain Management Center; Center for BrainHealth at University of Texas at Dallas; Nvivo Health in Beverly Hills; and Brain Optimization Lab in Miami.
Delphi-MD is being used in various applications including stroke recovery, traumatic brain injury (TBI) recovery, neuromodulation therapies, pain management programs, dementia care initiatives, movement disorder monitoring, cognitive resilience research, and preventive approaches to brain health.
Sandra Bond Chapman, PhD, Chief Director at the Center for BrainHealth at The University of Texas at Dallas said: “We are proud to be collaborating with QuantalX as they bring Delphi-MD into the commercial market. In our ongoing BrainHealth Project, we’ve seen how essential direct and objective neuro-functional insights are to understanding brain health. Bringing this level of quantitative data into routine clinical workflows is a vital step toward proactive and personalized brain care.”
QuantalX Neuroscience will present Delphi-MD at two upcoming industry events: the American Clinical Neurophysiology Society (ACNS) Annual Meeting from February 18–22 in New Orleans (Booth #204) and ViVE 2026 from February 22–25 in Los Angeles (Booth #1953-1).
The evaluation process with Delphi‑MD takes about 30–40 minutes per session in typical clinical settings. Results are standardized for repeatability over time. Additionally, evaluations performed with Delphi-MD qualify for reimbursement through a dedicated Current Procedural Terminology (CPT) code—helping integrate it into existing billing systems.
For more information about QuantalX Neuroscience or Delphi-MD visit https://quantalx.com/.
